Evidence map›Paper›PMID 33859951›Full record

ReviewFrontiers in cellular and infection microbiology2021

Wuhan to World: The COVID-19 Pandemic.

Ashok Kumar, Rita Singh, Jaskaran Kaur, Sweta Pandey, Vinita Sharma, Lovnish Thakur, Sangeeta Sati, Shailendra Mani, Shailendra Asthana, Tarun Kumar Sharma and 3 more

3 registry-linked trialsAbstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 102 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04979949 phase2completednot on this map

Double-Blind, Randomized, Controlled, Multi-Centered, Phase 2 Clinical Trial to Determine the Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2

TypeinterventionalSponsorHealth Institutes of TurkeyRan2021 to 2022Enrolled222ConditionsCOVID-19, Sars-CoV-2 InfectionArmsCoronaVac, Turkovac
NCT05077176 phase3completednot on this map

Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2

TypeinterventionalSponsorHealth Institutes of TurkeyRan2021 to 2024Enrolled4,340ConditionsCOVID-19, Sars-CoV-2 InfectionArmsCoronaVac, Turkovac
NCT06997653 phase2withdrawnnot on this mapstarted 2024, after this paper: background citation

Open-Label, Phase 2b Clinical Trial to Determine Efficacy, Safety, and Immunogenicity of Inactivated COVID-19 Vaccine (TURKOVAC) Against SARS-CoV-2 in Healthy Pregnant Women

TypeinterventionalSponsorHealth Institutes of TurkeyRan2024 to 2024Enrolled0ConditionsCOVID-19, SARS CoV 2 InfectionArmsTURKOVAC
3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Virtual Reality (VR) Technology for Treatment of Mental Health Problems during COVID-19: A Systematic Review.International journal of environmental research and public health · 2022
    Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Scientifica · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ashok KumarTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Rita SinghTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Jaskaran KaurTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Sweta PandeyTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Vinita SharmaTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Lovnish ThakurTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Sangeeta SatiTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Shailendra ManiTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Shailendra AsthanaTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Tarun Kumar SharmaTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Susmita ChaudhuriTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Sankar BhattacharyyaTranslational Health Science and Technology Institute (THSTI), Faridabad, India.
Niraj KumarTranslational Health Science and Technology Institute (THSTI), Faridabad, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is a Severe Acute Respiratory Syndrome (SARS), caused by SARS-CoV-2, a novel virus which belongs to the family

Indexed as

Global HealthPandemicsChinaCOVID-19HumansSARS-CoV-2coronavirusesCOVID-19diagnosticsSARS-CoV-2therapeuticstransmission

Identifiers

PMID33859951
PMCPMC8042280

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.